Back to Agenda
[S16] Promotion of Pediatric Drug Development by Industry, Government and Academia - What Has Changed, What Has Been Done and What Is Necessary for the Further Progress?
Session Chair(s)
Junko Sato, PhD
Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Varous measures are being created to promote pediatric drug development by industry, government and academia. From this perspective, efforts made in the past 1 year to promote the periatric development will be reviewed, and in the panel, issues surrounding the periatric drug development will be discussed in order to address them. A patient representative will also be invited to the panel discussion to proivde the patient viewpoints.
Speaker(s)
New Drug Development for Children’s Cancer - What has been done? What has changed?
Chitose Ogawa, MD
National Cancer Center Hospital, Japan
Chief, Department of Pediatric Oncology
Promotion of Pediatric Drug Development –What Has Changed, What Has Been Done and What Is Necessary for the Further Progress? –From the Perspective of the PMDA
Michiyo Sakiyama, MD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Associate Senior Scientist for Clinical Medicine, Office of Vaccines and Blood
Pediatric Clinical Development Update at Pfizer Japan
Takayuki Imaeda, MPharm, MS
Pfizer R&D Japan, Japan
Head of Regulatory Sciences
Have an account?